Clinical and Molecular Attributes and Evaluation of Pancreatic Cystic Neoplasm

Overview

Journal Biochim Biophys Acta Rev Cancer

Publisher Elsevier

Specialties Biochemistry
Biophysics
Oncology

Date 2022 Dec 19

PMID 36535512

Authors

Pratima Raut

Rama Krishna Nimmakayala

Surinder K Batra

Moorthy P Ponnusamy

Affiliations

Soon will be listed here.

Abstract

Intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs) are all considered "Pancreatic cystic neoplasms (PCNs)" and show a varying risk of developing into pancreatic ductal adenocarcinoma (PDAC). These lesions display different molecular characteristics, mutations, and clinical manifestations. A lack of detailed understanding of PCN subtype characteristics and their molecular mechanisms limits the development of efficient diagnostic tools and therapeutic strategies for these lesions. Proper in vivo mouse models that mimic human PCNs are also needed to study the molecular mechanisms and for therapeutic testing. A comprehensive understanding of the current status of PCN biology, mechanisms, current diagnostic methods, and therapies will help in the early detection and proper management of patients with these lesions and PDAC. This review aims to describe all these aspects of PCNs, specifically IPMNs, by describing the future perspectives.

Citing Articles

Molecular Pathology of Pancreatic Cystic Lesions with a Focus on Malignant Progression.

Hu Y, Jones D, Esnakula A, Krishna S, Chen W Cancers (Basel). 2024; 16(6).

PMID: 38539517 PMC: 10969285. DOI: 10.3390/cancers16061183.

References

Iodice S, Gandini S, Maisonneuve P, Lowenfels A . Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008; 393(4):535-45. DOI: 10.1007/s00423-007-0266-2. View

Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P . Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol. 2002; 160(5):1745-54. PMC: 1850868. DOI: 10.1016/S0002-9440(10)61121-2. View

Tanno S, Obara T, Koizumi K, Nakano Y, Osanai M, Mizukami Y . Risk of additional pancreatic cancer in patients with branch duct intraductal papillary-mucinous neoplasm. Clin J Gastroenterol. 2015; 2(6):365-370. DOI: 10.1007/s12328-009-0116-6. View

Lee K, Spata M, Bayne L, Buza E, Durham A, Allman D . Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. Cancer Discov. 2015; 6(3):256-69. PMC: 4783189. DOI: 10.1158/2159-8290.CD-15-0822. View

Omori Y, Ono Y, Tanino M, Karasaki H, Yamaguchi H, Furukawa T . Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features. Gastroenterology. 2018; 156(3):647-661.e2. DOI: 10.1053/j.gastro.2018.10.029. View

Yip-Schneider M, Simpson R, Carr R, Wu H, Fan H, Liu Z . Circulating Leptin and Branched Chain Amino Acids-Correlation with Intraductal Papillary Mucinous Neoplasm Dysplastic Grade. J Gastrointest Surg. 2018; 23(5):966-974. PMC: 6416083. DOI: 10.1007/s11605-018-3963-y. View

Hernandez-Barco Y, Bardeesy N, Ting D . No Cell Left Unturned: Intraductal Papillary Mucinous Neoplasm Heterogeneity. Clin Cancer Res. 2019; 25(7):2027-2029. PMC: 6445728. DOI: 10.1158/1078-0432.CCR-18-3877. View

Nakagawa T, Masuda A, Toyama H, Shiomi H, Zen Y, Sofue K . Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. Pancreas. 2017; 46(4):582-588. DOI: 10.1097/MPA.0000000000000761. View

Koo B, Spit M, Jordens I, Low T, Stange D, van de Wetering M . Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature. 2012; 488(7413):665-9. DOI: 10.1038/nature11308. View

10.

Ryan D, Hong T, Bardeesy N . Pancreatic adenocarcinoma. N Engl J Med. 2014; 371(11):1039-49. DOI: 10.1056/NEJMra1404198. View

11.

Kaur S, Kumar S, Momi N, Sasson A, Batra S . Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol. 2013; 10(10):607-20. PMC: 3934431. DOI: 10.1038/nrgastro.2013.120. View

12.

Tanaka M, Fernandez-Del Castillo C, Kamisawa T, Jang J, Levy P, Ohtsuka T . Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017; 17(5):738-753. DOI: 10.1016/j.pan.2017.07.007. View

13.

Gironella M, Seux M, Xie M, Cano C, Tomasini R, Gommeaux J . Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A. 2007; 104(41):16170-5. PMC: 2042180. DOI: 10.1073/pnas.0703942104. View

14.

Mayers J, Wu C, Clish C, Kraft P, Torrence M, Fiske B . Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014; 20(10):1193-1198. PMC: 4191991. DOI: 10.1038/nm.3686. View

15.

Vicentini C, Calore F, Nigita G, Fadda P, Simbolo M, Sperandio N . Exosomal miRNA signatures of pancreatic lesions. BMC Gastroenterol. 2020; 20(1):137. PMC: 7204029. DOI: 10.1186/s12876-020-01287-y. View

16.

Seshacharyulu P, Ponnusamy M, Haridas D, Jain M, Ganti A, Batra S . Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012; 16(1):15-31. PMC: 3291787. DOI: 10.1517/14728222.2011.648617. View

17.

Driehuis E, Van Hoeck A, Moore K, Kolders S, Francies H, Gulersonmez M . Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc Natl Acad Sci U S A. 2019; 116(52):26580-26590. PMC: 6936689. DOI: 10.1073/pnas.1911273116. View

18.

Hata T, Mizuma M, Motoi F, Ishida M, Morikawa T, Takadate T . Diagnostic and Prognostic Impact of Neutrophil-to-Lymphocyte Ratio for Intraductal Papillary Mucinous Neoplasms of the Pancreas With High-Grade Dysplasia and Associated Invasive Carcinoma. Pancreas. 2018; 48(1):99-106. DOI: 10.1097/MPA.0000000000001202. View

19.

Fontana F, Marzagalli M, Raimondi M, Zuco V, Zaffaroni N, Limonta P . δ-Tocotrienol sensitizes and re-sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPK-mediated apoptosis. Cell Prolif. 2021; 54(11):e13111. PMC: 8560608. DOI: 10.1111/cpr.13111. View

20.

Traverso L, Peralta E, RYAN Jr J, Kozarek R . Intraductal neoplasms of the pancreas. Am J Surg. 1998; 175(5):426-32. DOI: 10.1016/s0002-9610(98)00039-7. View